Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone
- PMID: 8751019
- DOI: 10.1007/BF00192356
Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone
Abstract
Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline. Hypokalaemia was used as the specific beta 2-adrenoceptor mediated effect. 8 healthy volunteers were given subcutaneous terbutaline 0.01 mg.kg-1 BW on 3 occasions over a 10-day experimental protocol: 1 Control experiment on Day 1; 2 After 7 days of oral terbutaline 5 mg t.i.d. (Day 8); and 3 After 8 days on oral terbutaline and 12 h after prednisone 100 mg orally (Day 10). The time course of the terbutaline concentrations and hypokalaemia was related using a pharmacokinetic-pharmacodynamic model. A sigmoid and a threshold Emax model were used to relate drug concentrations to effects. The oral terbutaline treatment caused a 35% increase in the distribution volume of SC terbutaline. After one week on oral terbutaline the concentration-effect relationship was shifted to the right and was steeper, with a higher EC50 of terbutaline and higher values for the apparent threshold concentration. These observations are compatible with a decrease in receptor numbers after 7 days of terbutaline in a system characterised by the presence of spare receptors. The data after prednisone pretreatment showed an apparent decline in the baseline plasma potassium concentrations that could be included in the Emax model. There was no change in the concentration-effect relationship 12 hours after prednisone.
Similar articles
-
Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.Clin Pharmacol Ther. 1987 Dec;42(6):627-33. doi: 10.1038/clpt.1987.210. Clin Pharmacol Ther. 1987. PMID: 2826064 Clinical Trial.
-
Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen.J Clin Invest. 1985 Sep;76(3):1096-101. doi: 10.1172/JCI112063. J Clin Invest. 1985. PMID: 2995446 Free PMC article.
-
Beta 2-agonist treatment reduces beta 2-sensitivity in alveolar macrophages despite corticosteroid treatment.Am J Respir Crit Care Med. 1996 Feb;153(2):576-81. doi: 10.1164/ajrccm.153.2.8564101. Am J Respir Crit Care Med. 1996. PMID: 8564101 Clinical Trial.
-
Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol.Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):342-62. Int J Clin Pharmacol Ther Toxicol. 1992. PMID: 1358833 Review.
-
The importance of being receptive.J Neuroimmunol. 1999 Dec;100(1-2):197-202. doi: 10.1016/s0165-5728(99)00194-0. J Neuroimmunol. 1999. PMID: 10695730 Review.
Cited by
-
Prevention by theophylline of beta-2-receptor down regulation in healthy subjects.Eur J Drug Metab Pharmacokinet. 2000 Jul-Dec;25(3-4):179-88. doi: 10.1007/BF03192311. Eur J Drug Metab Pharmacokinet. 2000. PMID: 11420887 Clinical Trial.
-
Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.Pharm Res. 1999 Feb;16(2):176-85. doi: 10.1023/a:1011907920641. Pharm Res. 1999. PMID: 10100300
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical